BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37737216)

  • 1. Comparison of Obesity-Related Indicators for Nonalcoholic Fatty Liver Disease Diagnosed by Transient Elastography.
    Tian X; Ding N; Su Y; Qin J
    Turk J Gastroenterol; 2023 Oct; 34(10):1078-1087. PubMed ID: 37737216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of obesity-related indices for identifying nonalcoholic fatty liver disease: a population-based cross-sectional study in China.
    Xie F; Pei Y; Zhou Q; Cao D; Wang Y
    Lipids Health Dis; 2021 Oct; 20(1):132. PubMed ID: 34629056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between body roundness index and non-alcoholic fatty liver disease detected by Fibroscan in America.
    Jiang N; Zhang S; Chu J; Yang N; Lu M
    J Clin Lab Anal; 2023 Oct; 37(19-20):e24973. PubMed ID: 37850486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
    Chan WK; Nik Mustapha NR; Mahadeva S
    J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients.
    Shen F; Zheng RD; Mi YQ; Wang XY; Pan Q; Chen GY; Cao HX; Chen ML; Xu L; Chen JN; Cao Y; Zhang RN; Xu LM; Fan JG
    World J Gastroenterol; 2014 Apr; 20(16):4702-11. PubMed ID: 24782622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective, Same-Day, Direct Comparison of Controlled Attenuation Parameter With the M vs the XL Probe in Patients With Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imaging-Proton Density Fat Fraction as the Standard.
    Caussy C; Brissot J; Singh S; Bassirian S; Hernandez C; Bettencourt R; Rizo E; Richards L; Sirlin CB; Loomba R
    Clin Gastroenterol Hepatol; 2020 Jul; 18(8):1842-1850.e6. PubMed ID: 31843596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Screening value and correlation of body measurement indices for metabolic syndrome in the population undergoing physical examinations in Chengdu during 2018-2020].
    Xue J; Ni G; Liu Y; Wan Z; Sun P
    Wei Sheng Yan Jiu; 2024 Jan; 53(1):21-29. PubMed ID: 38443169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 10 obesity-related indices for predicting hypertension based on ROC analysis in Chinese adults.
    Lee X; Gao Y; Zhang Y; Feng Y; Gao L; Wang A; Jiang Y; Huang H
    Front Public Health; 2022; 10():1042236. PubMed ID: 36504986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triglyceride Glucose Index and Related Parameters (Triglyceride Glucose-Body Mass Index and Triglyceride Glucose-Waist Circumference) Identify Nonalcoholic Fatty Liver and Liver Fibrosis in Individuals with Overweight/Obesity.
    Khamseh ME; Malek M; Abbasi R; Taheri H; Lahouti M; Alaei-Shahmiri F
    Metab Syndr Relat Disord; 2021 Apr; 19(3):167-173. PubMed ID: 33259744
    [No Abstract]   [Full Text] [Related]  

  • 10. Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017-2018.
    Truong E; Yeo YH; Cook-Wiens G; Muthiah M; Yang JD; Sundaram V; Chang D; Todo T; Kim IK; Lu SC; Setiawan VW; Wong VWS; Harrison SA; Alkhouri N; Noureddin M
    Hepatol Commun; 2022 Sep; 6(9):2253-2261. PubMed ID: 35527706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender Differences in the Relationships among Metabolic Syndrome and Various Obesity-Related Indices with Nonalcoholic Fatty Liver Disease in a Taiwanese Population.
    Lin IT; Lee MY; Wang CW; Wu DW; Chen SC
    Int J Environ Res Public Health; 2021 Jan; 18(3):. PubMed ID: 33498329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Efficacy of Anthropometric Indicators in Predicting Non-Alcoholic Fatty Liver Disease Using FibroScan
    Lee MS; Felipe-Dimog EB; Yang JF; Chen YY; Wu KT; Kuo HJ; Lin TC; Wang CL; Hsieh MH; Lin CY; Batsaikhan B; Ho CK; Wu MT; Dai CY
    Biomedicines; 2023 Sep; 11(9):. PubMed ID: 37760959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body mass index-based controlled attenuation parameter cut-offs for assessment of hepatic steatosis in non-alcoholic fatty liver disease.
    Shalimar ; Kumar R; Rout G; Kumar R; Yadav R; Das P; Aggarwal S; Gunjan D; Saraya A; Nayak B
    Indian J Gastroenterol; 2020 Feb; 39(1):32-41. PubMed ID: 32185692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The lipid accumulation product is a powerful tool to diagnose metabolic dysfunction-associated fatty liver disease in the United States adults.
    Li H; Zhang Y; Luo H; Lin R
    Front Endocrinol (Lausanne); 2022; 13():977625. PubMed ID: 36407325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The usefulness of obesity and lipid-related indices to predict the presence of Non-alcoholic fatty liver disease.
    Sheng G; Lu S; Xie Q; Peng N; Kuang M; Zou Y
    Lipids Health Dis; 2021 Oct; 20(1):134. PubMed ID: 34629059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New anthropometric indices or old ones: which perform better in estimating cardiovascular risks in Chinese adults.
    Wang F; Chen Y; Chang Y; Sun G; Sun Y
    BMC Cardiovasc Disord; 2018 Jan; 18(1):14. PubMed ID: 29378513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between bedtime at night and nonalcoholic fatty liver disease diagnosed by liver ultrasound transient elastography.
    Zhou J; Long Y; Ding N; Su Y
    Diabetes Res Clin Pract; 2022 Feb; 184():109195. PubMed ID: 35033597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.
    de Lédinghen V; Wong GL; Vergniol J; Chan HL; Hiriart JB; Chan AW; Chermak F; Choi PC; Foucher J; Chan CK; Merrouche W; Chim AM; Le Bail B; Wong VW
    J Gastroenterol Hepatol; 2016 Apr; 31(4):848-55. PubMed ID: 26514665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement.
    Huang Z; Ng K; Chen H; Deng W; Li Y
    Front Endocrinol (Lausanne); 2021; 12():739875. PubMed ID: 35173677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between Sarcopenic Obesity and Nonalcoholic Fatty Liver Disease and Fibrosis detected by Fibroscan.
    Wijarnpreecha K; Aby ES; Ahmed A; Kim D
    J Gastrointestin Liver Dis; 2021 Jun; 30(2):227-232. PubMed ID: 33951121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.